CoChat

Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia

Open access

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index; none of the 70 sources its claims cite is checked for support yet.

Abstract

Background: Routine monitoring of anti-malarial drugs is recommended for early detection of drug resistance and to inform national malaria treatment guidelines. In Ethiopia, the national treatment guidelines employ a species-specific approach. Artemether-lumefantrine (AL) and chloroquine (CQ) are the first-line schizonticidal treatments for Plasmodium falciparum and Plasmodium vivax, respectively. The National Malaria Control and Elimination Programme in Ethiopia is considering dihydroartemisinin-piperaquine (DHA/PPQ) as an alternative regimen for P. falciparum and P. vivax. Methods: The study assessed the clinical and parasitological efficacy of AL, CQ, and DHA/PPQ in four arms. Patients over 6 months and less than 18 years of age with uncomplicated malaria mono-infection were recruited and allocated to AL against P. falciparum and CQ against P. vivax. Patients 18 years or older with uncomplicated malaria mono-infection were recruited and randomized to AL or dihydroartemisinin-piperaquine (DHA/PPQ) against P. falciparum and CQ or DHA/PPQ for P. vivax. Patients were followed up for 28 (for CQ and AL) or 42 days (for DHA/PPQ) according to the WHO recommendations. Polymerase chain reaction (PCR)-corrected and uncorrected estimates were analysed by Kaplan Meier survival analysis and per protocol methods. Results: A total of 379 patients were enroled in four arms (n = 106, AL-P. falciparum; n = 75, DHA/PPQ- P. falciparum; n = 142, CQ-P. vivax; n = 56, DHA/PPQ-P. vivax). High PCR-corrected adequate clinical and parasitological response (ACPR) rates were observed at the primary end points of 28 days for AL and CQ and 42 days for DHA/PPQ. ACPR rates were 100% in AL-Pf (95% CI: 96–100), 98% in CQ-P. vivax (95% CI: 95–100) at 28 days, and 100% in the DHA/PPQ arms for both P. falciparum and P. vivax at 42 days. For secondary endpoints, by day three 99% of AL-P. falciparum patients (n = 101) cleared parasites and 100% were afebrile. For all other arms, 100% of patients cleared parasites and were afebrile by day three. No serious adverse events were reported. Conclusion: This study demonstrated high therapeutic efficacy for the anti-malarial drugs currently used by the malaria control programme in Ethiopia and provides information on the efficacy of DHA/PPQ for the treatment of P. falciparum and P. vivax as an alternative option.

Overview

CoChat Summary

TL;DR

In an open-label, four-arm therapeutic efficacy study in Ethiopia, artemether-lumefantrine (AL), chloroquine (CQ), and dihydroartemisinin-piperaquine (DHA/PPQ) all showed high efficacy against uncomplicated *Plasmodium falciparum* and *P. vivax* at their respective follow-up endpoints. DHA/PPQ achieved 100% PCR-corrected ACPR at day 42 for both species, supporting it as an alternative regimen.

Key findings

  • Among 379 enroled patients, PCR-corrected ACPR was 100% for AL against *P. falciparum* at day 28 (95% CI 96–100), 98% for CQ against *P. vivax* at day 28 (95% CI 95–100), and 100% for DHA/PPQ against both *P. falciparum* and *P. vivax* at day 42.
  • By day 3, 99% of AL-treated *P. falciparum* patients (n = 101) cleared parasites and 100% were afebrile; in all other arms, 100% cleared parasites and were afebrile by day 3. No serious adverse events were reported.
  • Among 50 day-0 *P. falciparum* samples sequenced, no *pfk13* artemisinin-resistance-associated mutants were observed; *pfmdr1* Y184F was present in 73%, N86Y in 2%, S1034N in 2%, and the NFD haplotype in 36/50 (75%).
  • The 42-day ACPR for CQ against *P. vivax* was 82% overall (not a primary outcome), with site-specific values of 86.0% at Felegeselam and 97.7% at Arbaminch.

Methods

  • Open-label, four-arm therapeutic efficacy trial at two Ethiopian health centres (Felegeselam, Pawe; Arbaminch), September–December 2017. Patients >6 months with uncomplicated mono-infection were enroled: those <18 years received AL for *P. falciparum* or CQ for *P. vivax*; those ≥18 years were randomized to AL or DHA/PPQ for *P. falciparum* and CQ or DHA/PPQ for *P. vivax*. Follow-up was 28 days for AL/CQ and 42 days for DHA/PPQ.
  • Outcomes were analysed by per-protocol and Kaplan–Meier methods, with PCR correction to day 28 for AL and CQ. Laboratory methods included microscopy, haemoglobin measurement, parasite genotyping at CDC, and sequencing of *pfk13* and *pfmdr1*.

Limitations

  • Stated by the authors: DHA/PPQ arms had lower-than-targeted enrolment because the study was not extended past the high transmission season; DHA/PPQ was studied only in adults ≥18 years, limiting generalizability to younger age groups; the study was powered per arm and not for between-arm comparisons; insufficient site-specific numbers required pooling data from two sites; adverse event data were not presented because ongoing symptoms were erroneously recorded as adverse events; the second AL dose was unobserved; and genotype investigation was limited to 50 samples without piperaquine or CQ resistance markers.
  • Evident from the text: the trial was open-label, with no blinding described; PCR correction was only performed to day 28 for AL and CQ, so later CQ recurrences were not PCR-corrected; and the CQ 42-day ACPR of 82% was reported only as a non-primary outcome without confidence intervals.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12936-022-04350-z

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Map of the study area. A Map of Ethiopia with study areas in Benishangul-Gumuz and Southern Nations and Nationalities Peoples’ (SNNP) Regions noted in purple. B Location of Pawe in Metekel Zone, Benishangul-Gumuz Region. C Location of Arbaminch in Gamu-Gofa Zone, SNNP Region. NB B and C are not to scale)
Fig. 1 Map of the study area. A Map of Ethiopia with study areas in Benishangul-Gumuz and Southern Nations and Nationalities Peoples’ (SNNP) Regions noted in purple. B Location of Pawe in Metekel Zone, Benishangul-Gumuz Region. C Location of Arbaminch in Gamu-Gofa Zone, SNNP Region. NB B and C are not to scale)CC BY · PubMed Central
Fig. 2 Flow chart of the study enrolment and follow-up. Lost lost to follow up, Violation protocol violation, AL Artemether-Lumefantrine, DHA/PPQ Dihydroartemisinin-Piperaquine, CQ Chloroquine
Fig. 2 Flow chart of the study enrolment and follow-up. Lost lost to follow up, Violation protocol violation, AL Artemether-Lumefantrine, DHA/PPQ Dihydroartemisinin-Piperaquine, CQ ChloroquineCC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 28 Not checked · 55 Own results and interpretations

23 more claims

Create a free account to see all 84 claims and to verify the 69 references still open.

See all claims — free account
  • It may state two separate claims as one. 42
  • Probably not a substantial claim. 23
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Ministry of Health Federal Democratic Republic of Ethiopia. Ethiopian Malaria Review Document. Addis Ababa, Ethiopia; 2020.

Cited by

See all 20

Metadata

Authors
Assefa, A., Mohammed, H., Anand, A., Abera, A., Sime, H., Minta, A. A., Tadesse, M., Tadesse, Y., Girma, S., Bekele, W., Etana, K., Alemayehu, B. H., Teka, H., Dilu, D., Haile, M., Solomon, H., Moriarty, L. F., Zhou, Z., Svigel, S. S., Ezema, B., Tasew, G., Woyessa, A., Hwang, J., & Murphy, M.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Ethiopian Public Health Institute (ET)
  • Centers for Disease Control and Prevention (US)
  • ICAP Global Health (US)
  • U.S. President's Malaria Initiative (US)
  • World Health Organization (CH)
  • Federal Ministry of Health (ET)
Corresponding author
Assefa, Ashenafi
Venue
Malaria Journal
Published
2022-12-01
Volume
21
Issue
1
Pages
359-359
ISSN
1475-2875 (ISSN-L)
OpenAlex
W4310640244
Cited by
20
References
43
Citations by year
2026: 6 · 2025: 4 · 2024: 6 · 2023: 4
FWCI
2.34
Type
journal article
Language
en
Open access
Licence
Locations
  • Malaria Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UNC Libraries
  • Greater South Information System
Funders
  • Global Fund to Fight AIDS, Tuberculosis and Malaria
  • World Health Organization
  • Bundesministerium für Gesundheit
  • Centers for Disease Control and Prevention
  • President's Malaria Initiative
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
artemether-lumefantrine, dihydroartemisinin-piperaquine, chloroquine, Plasmodium falciparum, Plasmodium vivax, uncomplicated malaria, antimalarial drug efficacy, treatment failure, malaria treatment guidelines, Ethiopia, antimicrobial resistance surveillance
MeSH terms
Artemether, Artemether, Lumefantrine Drug Combination, Antimalarials, Chloroquine, Ethiopia, Humans, Piperazines, Plasmodium falciparum, Plasmodium vivax, Quinolines, Malaria, Falciparum, Malaria, Vivax, Artemisinins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia. https://app.cochat.ai/papers/10.1186/s12936-022-04350-z
The paper
Assefa, A., Mohammed, H., Anand, A., Abera, A., Sime, H., Minta, A. A., Tadesse, M., Tadesse, Y., Girma, S., Bekele, W., Etana, K., Alemayehu, B. H., Teka, H., Dilu, D., Haile, M., Solomon, H., Moriarty, L. F., Zhou, Z., Svigel, S. S., . . . Murphy, M. (2022). Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia. Malaria Journal. https://doi.org/10.1186/s12936-022-04350-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.